Epizyme Closes $40M Series B Financing adding NEA to Investor Syndicate

Epizyme, Inc., a Cambridge, MA-based biopharmaceutical company that creates innovative drugs for major diseases based on discoveries emerging from the field of epigenetics, announced the participation of New Enterprise Associates (NEA) in its Series B financing round, bringing the total raised to $40m.
NEA joins an investor group that includes BCC, Amgen Ventures, Astellas Venture, MPM Capital and Kleiner Perkins Caufield and Byers (KPCB).
In conjunction with the second close of the Series B financing, David M. Mott, NEA General Partner, joins the Company’s Board of Directors.

Join the discussion